Viridian Therapeutics
VRDN
128 hedge funds and large institutions have $1.12B invested in Viridian Therapeutics in 2023 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 69 increasing their positions, 25 reducing their positions, and 24 closing their positions.
176% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 25
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
8.86% more ownership
Funds ownership: 100.39% → 109.25% (+8.9%)
2% more capital invested
Capital invested by funds: $1.1B → $1.12B (+$25.4M)
5% less funds holding
Funds holding: 135 → 128 (-7)
29% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 24
37% less call options, than puts
Call options by funds: $11.9M | Put options by funds: $18.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$30.9M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$26.9M |
| 3 |
Millennium Management
New York
|
+$18.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$13.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$16.9M |
| 2 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$14.4M |
| 3 |
Morgan Stanley
New York
|
-$9.32M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$8.28M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$6.72M |
VRDN Hedge Fund Activity: Q2 2023 in Review
128 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2023, worth a combined $1.12B — up 2.3% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of VRDN and 17 opened new positions — a net loss of 7 holders — while 25 trimmed existing stakes and 69 added.
The largest buyer was Braidwell, opening a new position worth an estimated $30.9M. The largest seller was TCG Crossover Management, exiting entirely with an estimated $16.9M sold.
- 128 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2023, down from 135 in Q1 2023.
- Funds reported $1.12B of Viridian Therapeutics stock for Q2 2023, up 2.3% quarter-over-quarter.
- 17 funds opened new Viridian Therapeutics positions in Q2 2023 and 24 closed out, a net change of -7 holders.
- The largest Viridian Therapeutics buyer in Q2 2023 was Braidwell, an estimated $30.9M added.
- The largest Viridian Therapeutics seller in Q2 2023 was TCG Crossover Management, an estimated $16.9M sold.
Based on aggregated 13F filings for Q2 2023.